Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 161-167

  Krasner, Carolyn N ^a   Poveda, Andres ^b   Herzog, Thomas J ^c   Vermorken, Jan B ^d   Kaye, Stanley B ^e   Nieto, Antonio ^f   Claret, Pilar Lardelli ^f   Park, Youn Choi ^g   Parekh, Trilok ^g   Monk, Bradley J ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c NewYork Presbyterian Hospital   (United States)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f PHARMAMAR S A   (Spain)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DOXIL ; Patient reported outcome; Pegylated liposomal doxorubicin; Relapsed ovarian cancer; Trabectedin; Yondelis

Indexed keywords

DOXORUBICIN; TRABECTEDIN;

ADULT; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEALTH INDEX SCORE; HEALTH STATE ON THE VISUAL ANALOG SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; QUESTIONNAIRES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84865675658     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.034     Document Type: Article

References (29)

1. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
2. J.M. Del Campo, E. Felip, D. Rubio, R. Vidal, B. Bermejo, and R. Colomer Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment Gynecol Oncol 53 1994 27 32
3. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
4. K. Aabo, M. Adams, P. Adnitt, D.S. Alberts, A. Athanazziou, and V. Barley Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78 1998 1479 1487
5. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
6. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708
7. M.J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, C. Mangioni, and E. Simonsen Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gynecol Cancer 13 Suppl. 2 2003 144 148
8. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, and R. Atkinson Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
9. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
10. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
11. A. Patnaik, C. Doyle, and A.M. Oza Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost Anticancer Drugs 9 1998 869 878
12. E.A. Calhoun, D.A. Fishman, J.R. Lurain, E.E. Welshman, and C.L. Bennett A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians Gynecol Oncol 93 2004 164 169
13. L.J. Havrilesky, G. Broadwater, D.M. Davis, K.C. Nolte, J.C. Barnett, and E.R. Myers Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment Gynecol Oncol 113 2009 216 220
14. V.E. von Gruenigen, H.Q. Huang, K.M. Gil, H.E. Gibbons, B.J. Monk, and P.G. Rose Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials Cancer 115 2009 4857 4864
15. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, and A. Santoro Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 2004 440 449
16. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
17. V.E. von Gruenigen, H.E. Frasure, E.L. Jenison, M.P. Hopkins, and K.M. Gil Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy Gynecol Oncol 103 2006 120 126
18. L. Wenzel, H.Q. Huang, B.J. Monk, P.G. Rose, and D. Cella Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 23 2005 5605 5612
19. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, and N.J. Duez The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
20. A. Montazeri, J. McEwen, and C.R. Gillis Quality of life in patients with ovarian cancer: current state of research Support Care Cancer 4 1996 169 179
21. D. Osoba, B. Zee, J. Pater, D. Warr, L. Kaizer, and J. Latreille Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Qual Life Res 3 1994 353 364
22. E. Greimel, A. Bottomley, A. Cull, A.C. Waldenstrom, J. Arraras, and L. Chauvenet An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer Eur J Cancer 39 2003 1402 1408
23. H.M. van Agt, M.L. Essink-Bot, P.F. Krabbe, and G.J. Bonsel Test-retest reliability of health state valuations collected with the EuroQol questionnaire Soc Sci Med 39 1994 1537 1544
24. A. Cull, S. Howat, E. Greimel, A.C. Waldenstrom, J. Arraras, and A. Kudelka EORTC Quality of Life Group [European Organization for Research and Treatment of Cancer]; Scottish Gynaecological Cancer Trials Group. Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37 2001 47 53
25. M.A. Dinan, K.L. Compton, J.K. Dhillon, B.G. Hammill, E.M. Dewitt, and K.P. Weinfurt Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials Med Care 49 2011 415 419
26. D.L. Fairclough Design and analysis of quality of life studies in clinical trials 2010 CRC Press Boca Raton, FL
27. T. Lowe, B. Ferrell, and L. Leong Quality-of-life issues in the management of epithelial ovarian cancer Curr Treat Options Oncol 8 2007 402 416
28. S.B. Kaye, N. Colombo, B.J. Monk, S. Tjulandin, B. Kong, and M. Roy Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 2010 49 58
29. A. Poveda, I. Vergote, S. Tjulandin, B. Kong, M. Roy, and S. Chan Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 22 2010 39 48